PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Oral drug may improve survival in men with metastatic prostate cancer

2013-11-20
(Press-News.org) Contact information: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Oral drug may improve survival in men with metastatic prostate cancer DURHAM, N.C. – An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

The study, published on Nov. 19, 2013, in the journal Clinical Cancer Research, adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer.

"While all subgroups in the clinical trial benefited from tasquinimod, those whose cancer metastasized to their bones had the greatest benefit in terms of delaying the time from the start of treatment to when the cancer progressed," said lead author Andrew J. Armstrong, M.D., ScM, associate professor of medicine at the Duke Cancer Institute. "This group of men also seemed to have a longer survival benefit when we followed them over several years."

Tasquinimod, a drug in development by Active Biotech in partnership with Ipsen, is an oral therapy that activates the body's immune system to fight cancer. Its mechanism is not fully understood, but it appears to affect the function of myeloid-derived suppressor cells, which are found in increased numbers in cancer patients. Tasquinimod is also known to block tumor blood vessel growth, a process termed angiogenesis.

New treatments approved in recent years have given physicians and patients additional options to fight prostate cancer, but the therapies typically only extend patients' lives by three to five months. New drugs that increase survival – without serious side effects – are still needed.

In this phase II clinical trial, funded by Active Biotech, researchers studied the use of tasquinimod among men with metastatic castration-resistant prostate cancer, an advanced form of the disease that does not respond to hormonal therapy. The study enrolled 201 men who were followed for approximately three years, with 134 randomly assigned to receive tasquinimod and 67 given placebo.

The researchers measured patients' overall survival, whether their cancer progressed, and the drug's safety and tolerability. They also conducted studies of biomarkers to better understand how tasquinimod stimulates the immune system.

Armstrong and his colleagues found that men taking tasquinimod saw no cancer progression for an average of 7.6 months, compared with 3.3 months for placebo. Men whose cancer had already metastasized to their bones and took tasquinimod remained progression-free for even longer – 8.8 months, compared with 3.4 months for placebo.

"By delaying the onset of symptoms or growth of metastatic tumors, tasquinimod may allow men to put off other treatments, such as chemotherapy, and maintain a high quality of life," Armstrong said. "That's an important goal for many patients and providers."

Men taking tasquinimod survived 33.4 months on average, versus 30.4 months with placebo. However, those whose cancer had already metastasized to their bones survived an average of 34.2 months, compared with 27.1 months for placebo, a seven-month difference. This improvement in survival with tasquinimod persisted when statistical adjustments were made for other factors such as PSA level, PSA doubling time, lactate dehydrogenase (LDH) levels, and the presence of anemia, each of which were important prognostic factors.

The researchers also identified certain predictors of who would benefit most from tasquinimod, such as lower baseline PSA levels or other biomarkers.

The treatment was considered safe with low to moderate side effects, which included mild gastrointestinal issues, muscle and joint pains, and fatigue.

Based on results from the phase II clinical trial, tasquinimod is now being evaluated in an international phase III trial focusing on men whose prostate cancer has spread to their bones and become resistant to hormonal therapies.

"We still need to do more research to understand the efficacy and mechanism of action of tasquinimod, who benefits the most from it, how it fits into a treatment regimen, and how it could be used in combination with other therapies," Armstrong said. "In addition, tasquinimod is not a prostate cancer-specific drug. If the phase III trial shows that tasquinimod is effective and safe, this opens the door for evaluating the immunotherapy in other cancers."

### In addition to Armstrong, study authors include Michael Häggman of University Hospital of Uppsala in Sweden; Walter Stadler of the University of Chicago; Jeffrey Gingrich of the University of Pittsburgh; Vasily Assikis of Peachtree Hematology Oncology Consultants in Atlanta; Jonathan Polikoff of Kaiser Permanente Medical Group in San Diego; Jan-Erik Damber of Sahlgrenska University Hospital in Sweden; Laurence Belkoff of Urologic Consultants of Southeastern Pennsylvania; Örjan Nordle and Göran Forsberg of Active Biotech AB; Michael Carducci of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; and Roberto Pili of Roswell Park Cancer Institute in Buffalo. Armstrong and Pili received research funding from Active Biotech. Nordle and Forsberg are employees and shareholders of Active Biotech. The research was conducted within the Department of Defense Prostate Cancer Clinical Trials Consortium, a 13-site clinical research group working to design, implement and complete phase I and phase II trials in prostate cancer.


ELSE PRESS RELEASES FROM THIS DATE:

New case studies link smoking synthetic marijuana with stroke in healthy, young adults

2013-11-20
New case studies link smoking synthetic marijuana with stroke in healthy, young adults University of South Florida neurologists report both patients experienced ischemic strokes soon after smoking the street drug spice Tampa, FL (Nov. 19, ...

Sex of speaker affects listener language processing

2013-11-20
Sex of speaker affects listener language processing LAWRENCE — Whether we process language we hear without regard to anything about the speaker is a longstanding scientific debate. But it wasn't until University of Kansas scientists set up an experiment showing ...

HIV virus spread and evolution studied through computer modeling

2013-11-20
HIV virus spread and evolution studied through computer modeling LOS ALAMOS, N.M., November 19, 2013—Researchers at Los Alamos National Laboratory are investigating the complex relationships between the spread of the HIV virus in a population (epidemiology) ...

Blacks have less access to cancer specialists, treatment

2013-11-20
Blacks have less access to cancer specialists, treatment UC San Diego study suggests racial inequality leads to higher mortality Researchers at the University of California, San Diego School of Medicine say metastatic colorectal cancer patients of African-American ...

What water looks like to DNA

2013-11-20
What water looks like to DNA New computational method described in the Journal of Chemical Physics allows researchers to predict how biological molecules interact with water WASHINGTON D.C. Nov. 19, 2013 -- A team of biochemists and mathematicians have ...

Stanford study could lead to paradigm shift in organic solar cell research

2013-11-20
Stanford study could lead to paradigm shift in organic solar cell research Organic solar cells have long been touted as lightweight, low-cost alternatives to rigid solar panels made of silicon. Dramatic improvements in the efficiency of organic photovoltaics have ...

New study finds no benefit to selecting dose of blood thinner based on patients' genetic makeup

2013-11-20
New study finds no benefit to selecting dose of blood thinner based on patients' genetic makeup Largest randomized, multi-center controlled trial of gene-based strategy for warfarin dosing also found better outcome for African ...

Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation

2013-11-20
Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation Boston, MA – According to the United States Centers for Disease Control and Prevention, over 800,000 ...

Bedroom access to screen-based media may contribute to sleep problems in boys with autism, MU researchers find

2013-11-20
Bedroom access to screen-based media may contribute to sleep problems in boys with autism, MU researchers find Having bedroom access to television, computers or video games is linked to less sleep in boys with autism spectrum disorder (ASD), a team of University ...

Higher emotional intelligence leads to better decision-making

2013-11-20
Higher emotional intelligence leads to better decision-making Toronto – The anxiety people feel making investment decisions may have more to do with the traffic they dealt with earlier than the potential consequences they face with the ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] Oral drug may improve survival in men with metastatic prostate cancer